Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- macitentan
- Targretin (bexarotene)
Interactions between your drugs
bexarotene macitentan
Applies to: Targretin (bexarotene), macitentan
MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme. In ten healthy male subjects pretreated with macitentan (30 mg initially, followed by 10 mg once daily) for 5 days, coadministration with the potent CYP450 3A4 inducer rifampin (600 mg once daily) on days 6 through 12 reduced macitentan systemic exposure (AUC) by 79% and trough plasma concentration (Cmin) by 93% compared to macitentan administered alone. There was no significant effect on the AUC of the active metabolite, which has been reported to be approximately 5-fold less potent than macitentan in vitro, but whose systemic exposure in human is 2.5-fold higher than that of macitentan.
MANAGEMENT: Caution is advised when macitentan is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.
References (2)
- (2013) "Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc
- Bruderer S, Aanismaa P, Homery MC, et al. (2012) "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J, 14, p. 68-78
Drug and food interactions
bexarotene food
Applies to: Targretin (bexarotene)
ADJUST DOSING INTERVAL: Food may enhance the oral bioavailability of bexarotene. In one clinical study, bexarotene peak plasma concentration (Cmax) and systemic exposure (AUC) resulting from a 75 to 300 mg dose were 35% and 48% higher, respectively, when administered after a fat-containing meal relative to a glucose solution. In all clinical trials, patients were instructed to take bexarotene with or immediately following a meal.
Coadministration with inhibitors of CYP450 3A4 such as grapefruit juice may theoretically increase the plasma concentrations of bexarotene. In vitro studies suggest that bexarotene is metabolized by CYP450 3A4. However, concomitant administration with multiple doses of ketoconazole, a potent CYP450 3A4 inhibitor, did not alter bexarotene plasma concentrations, which would imply that bexarotene elimination is not substantially dependent on CYP450 3A4 metabolism in vivo.
MANAGEMENT: Because safety and efficacy data are based upon administration with food, bexarotene should be administered once daily with a meal. Patients may want to avoid consuming large amounts of grapefruit or grapefruit juice.
References (2)
- (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cialis
Cialis (tadalafil) increase increases blood flow to a certain area of the body and is used to treat ...
Viagra
Viagra (sildenafil) is used to treat erectile dysfunction or impotence in men. Includes Viagra side ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Adcirca
Adcirca is used to treat pulmonary arterial hypertension. Learn about side effects, interactions ...
Revatio
Revatio (sildenafil) is used to treat pulmonary arterial hypertension. Includes Revatio side ...
Opsumit
Opsumit (macitentan) is used to treat pulmonary arterial hypertension. Includes Opsumit side ...
Adempas
Adempas (riociguat) is used to treat pulmonary hypertension. Includes Adempas side effects ...
Winrevair
Winrevair (sotatercept) is an injectable activin signaling inhibitor that can be self-administered ...
Uptravi
Uptravi lowers blood pressure in your lungs by dilating blood vessels that supply blood to the ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.